Bromhexine PCD Pharma Franchise Company
Cafoli Lifecare offers a Bromhexine range of 5 formulations across syrup and tablets, manufactured in WHO-GMP certified facilities. Distributors building a respiratory and cough-cold portfolio can secure district-wise monopoly franchise rights with full promotional support.
What is Bromhexine?
Bromhexine is a mucolytic agent that thins and loosens respiratory mucus by depolymerising mucopolysaccharide fibres, making cough more productive and easing clearance of phlegm. It is widely used in productive cough and respiratory disorders with thick, sticky secretions. Reference: PubChem - Bromhexine.
Available Forms
The Cafoli Bromhexine portfolio includes oral Syrup and Tablets, often combined with expectorants, terbutaline, guaiphenesin and antihistamines in cough formulations. Contact us for current pack presentations and combinations.
Therapeutic Applications
Bromhexine is prescribed for productive cough associated with bronchitis, respiratory tract infection and other conditions with viscid sputum. Prescribers include chest physicians, paediatricians, ENT specialists and general practitioners.
Why Bromhexine is a High-Potential Molecule for Distributors
Cough and cold is the single highest-frequency reason for OPD visits in India, and mucolytic-expectorant syrups move in very high seasonal volume across every chemist. Bromhexine is a low-cost, universally accepted cough-formula ingredient, so it delivers dependable, fast-turnover retail sales that anchor a respiratory range.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.
References
- PubChem: Bromhexine
- PubMed: bromhexine mucolytic in productive cough
- MedlinePlus: Cough
Our formulations of Bromhexine find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: